Morphological Predictors of Short-Term Response to Intravitreal Bevacizumab in Macular Edema Due to Retinal Vein Occlusion
| Autor: | Madeira, Carolina, Moleiro, Ana, Godinho, Gonçalo, Penas, Susana, Pedrosa, Catarina, Falcão, Manuel, Brandão, Elisete, Falcão-Reis, Fernando, Beato, João |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| DOI: | 10.48560/rspo.22578 |
| Popis: | INTRODUCTION: Our purpose was to identify morphological predictive factors of short-term macular functional and anatomical outcomes after monthly intravitreal bevacizumab for the treatment of macular edema (ME) due to central (CRVO) and branch retinal vein occlusion (BRVO). METhODS: Retrospective study of patients with ME secondary to CRVO or BRVO under monthly treatment with intravitreal injections of bevacizumab. Only treatment naïve patients, with center-involved ME of ≥305 μm in women and ≥320 μm in men on baseline Spectral-domain OCT (SD-OCT) (Heidelberg Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany) were included. Resolution of ME was defined as central macular thickness (CMT) less than 300 μm, no subretinal and no intraretinal fluid. Demographic and clinical parameters, best-corrected visual acuity (BCVA) in ETDRS logarithmic scale and SD-OCT images were reviewed at baseline and at 4 months. SD-OCT morphologic features in the central 1.0-mm diameter circle were checked for disorganization of the retinal inner layers (DRIL), ellipsoid zone (EZ) and external limiting membrane (ELM) disruption, presence and location of intraretinal hyperreflective foci (HRF) cysts, subretinal and intraretinal fluid, and vitreoretinal interface status. RESULTS: The study enrolled 61 eyes of 61 patients, 29 (47.5%) with CRVO and 32 (52.5%) with BRVO. At 4 months, patients had received a mean number of 3.2±2.7 bevacizumab injections. Mean BCVA was 32±27 ETDRS letters at baseline and improved to 44±27 at 4 months (p Revista Sociedade Portuguesa de Oftalmologia, Vol. 46 N.º 2 (2022) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|